![](/imager/uploads/21592/freenome-funding-image_2022-03-08-001311_zbat_6439e647a38ed5b4d852739476ebaac9.webp)
Today, biopsies and scans aren’t the only ways to detect cancer; tumors also shed DNA, RNA, and proteins that can be detected in the bloodstream. Freenome is developing multiomics tests that use machine learning to detect complex patterns in both tumor-derived and non-tumor-derived biomarkers, making it possible to diagnose cancers earlier, when they’re more treatable. The company began with a blood-based test for colorectal cancer and is preparing for large studies of tests for multiple cancers.
News & Insights
Explore Companies
![](/imager/uploads/logos/58681/Avicenna_logo_black_117378e58441a39758ec294c229f7090.webp)
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
![](/imager/uploads/logos/58643/latus-logo-copy_117378e58441a39758ec294c229f7090.webp)
![](/imager/uploads/Companies/Latus/58650/Latus-lab_6439e647a38ed5b4d852739476ebaac9.webp)
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
![](/imager/uploads/logos/57002/radionetics-logo_black_117378e58441a39758ec294c229f7090.webp)
![](/imager/uploads/Companies/Radionetics/57003/Radionetics_6439e647a38ed5b4d852739476ebaac9.webp)
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
![](/imager/uploads/logos/55895/DVLP-logo-black_117378e58441a39758ec294c229f7090.webp)
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing